US Topical Pain Relief Market to Capture a CAGR of 4.67% Between 2023 and 2032, While Touching Approximately USD 4,466.79 Million by 2032 – The Brainy Insights


The US cannabis market will expand as a result of the increasing legalisation of cannabis in the country. Also, the surge in the prevalence of joint pains and arthritis is one reason for the growth of the topical pain relief market in the US.

Newark, Oct. 23, 2023 (GLOBE NEWSWIRE) — The Brainy Insights estimates that the USD 2829.92 million in 2022 US topical pain relief market will reach USD 4466.79 million in 2032. Since topical pain remedies are applied directly to the site of pain, they provide focused relief, one of their many significant advantages over oral painkillers. Merely a small amount of the oral medication reaches the intended target because it is distributed throughout the body. These have less negative effects than oral drugs. Topical pain relievers have several benefits, including zero drug tolerance and fewer side effects. Moreover, over-the-counter topical pain relievers are widely accessible and provide immediate relief without a prescription. This market is mainly driven in the United States by the rise in bone-related disorders such as arthritis. Moreover, diabetic neuropathy causes pain. In addition, the US’s senior population is expanding, and topical painkillers are becoming more and more popular due to their less negative effects. Sports players are starting to show an interest in these products as well.

Request to Download Sample Research Report –


Report Coverage Details

Report Coverage Details
Forecast Period 2023–2032
Base Year 2022
Market Size in 2022 USD 2,829.92 Million
Market Size in 2032 USD 4,466.79 Million
CAGR 4.67%
No. of Pages in Report 236
Segments Covered Therapeutic class, Type, Formulation, Distribution Channel
  • Growing arthritis cases in the US
  • The growing geriatric population in the US
Opportunities Growing e-commerce platform
Restraints Unpleasant smell and side effects

Key Insight of the US Topical Pain Relief Market

The non-opioids segment dominated the market, with a market share of around 78.45% in 2022.

The therapeutic class segment is divided into non-opioids and opioids. The non-opioids segment dominated the market, with a share of around 78.45% in 2022.

The over-the-counter pain relief segment dominated the market, with a market share of around 61.44% in 2022.

The type segment is divided into prescription pain relief and over-the-counter pain relief. The over-the-counter pain relief segment dominated the market, with a market share of around 61.44% in 2022.

The cream segment dominated the market, with a market share of around 52.12% in 2022.

The formulation segment is divided into cream, gel and others. The cream segment dominated the market, with a share of around 52.12% in 2022.

The offline segment dominated the market, with a market share of around 56.87% in 2022.

The distribution channel segment is divided into online and offline. The offline segment dominated the market, with a share of around 56.87% in 2022.

Advancement in market

Under the brand name Moore Relief Dermaceuticals, two new products have been developed by renowned dermatologist Dr Milton D. Moore, founder and CEO of Moore Unique Skin Care, LLC and Moore Unique Dermatology: Moore Relief Pain Discomfort Lotion and Moore Relief Skin Revitalising & Burn Lotion. Developed initially as moisturising remedies for skin-irritating disorders such as eczema. Fast-acting, efficient treatments that aid in healing burn wounds and relieving neuropathic skin discomfort include Moore Relief Pain Discomfort Lotion and Moore Relief Skin Revitalising & Burn Lotion. These two patent-pending Moore Relief Dermaceuticals products are made with natural components, including anti-inflammatory and moisturising ingredients like argan oil, aloe vera, and algae extracts.

Market Dynamics

Driver: Increasing number of US instances of arthritis.

It has been noted that arthritis is now the leading cause of disability in the US. Roughly 59 million US adults—roughly 1 in 4 US adults—were diagnosed with arthritis, according to one study. From 2013 to 2015, it increased by more than 4 million. People with arthritis have limited movement and overall functionality, which limits their activities. According to another study, the overall number of adult Americans who experience difficulties in their daily activities due to arthritis has climbed dramatically from 23.7 million in 2013–2015 to 25.7 million in 2016–2018. These factors ultimately drive the US market for topical pain treatment.

Restraints: Odour and adverse consequences.

Although topical painkillers are becoming more and more popular in the US, they may have unpleasant side effects and irritate skin. Additionally, these products’ strong aromas or disagreeable smells may make users and those around them uncomfortable. Each of these issues is restraining the market.

Opportunities: expanding e-commerce network.

The emergence of e-commerce platforms has been essential in the growth of the medical business because it has made online pharmacies accessible. Online pharmacies are expanding, making obtaining medications like topical analgesics that don’t usually require a prescription easier. Therefore, it’s simple to acquire topical medications online. The current pattern indicates that online pharmacies are expanding as demand for painkillers rises. There are also a tonne of cutting-edge new products available online. These factors will eventually drive the US topical pain relief market during the projected period.

Challenges: stringent regulatory norms.

Since these products are used by consumers directly onto their skin, it is possible that they may cause severe damage to the user if damaged in any way. Therefore, these products are subjected to strict monitoring and regulation and will challenge the market’s growth.

Interested to Procure the Research Report? Inquire Before Buying –

Some of the major players operating in the US topical pain relief market are:

• GlaxosmithklinePlc (GSK)
• Reckitt Benckiser Group Plc.
• AdvacarePharma
• Topical Biomedics, Inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Nestlé S.A.
• Sanofi
• Novartis AG
• Pfizer Inc.

Key Segments covered in the market:

By Therapeutic Class

• Non-Opioids
• Opioids

By Type

• Prescription Pain Relief
• Over-The-Counter Pain Relief

By Formulation

• Cream
• Gel
• Others

By Distribution Channel

• Online
• Offline

By Region

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, the UK, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America)
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Have a question? Speak to Research Analyst-

About the report:

The market is analyzed based on value (USD Billion). All the segments have been analyzed on a worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report analyses driving factors, opportunities, restraints, and challenges to gain critical market insight. The study includes Porter’s five forces model, attractiveness analysis, Product analysis, supply and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients’ objectives of high-quality output within a short span of time. We provide both customized (clients’ specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients’ requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D
Head of Business Development
Phone: +1-315-215-1633
Email: [email protected] 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.